{{Drugbox
| IUPAC_name = [(''E'')-1-(3-Cyclopentyloxy-4-methoxyphenyl)ethylideneamino] carbamate
| image = Filaminast.svg

<!--Clinical data-->
| tradename =
| pregnancy_category =
| legal_status = Development terminated
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number = 141184-34-1
| ATC_prefix = None
| ATC_suffix =
| PubChem = 9578243
| DrugBank = DB02660
| ChemSpiderID = 7852607
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CDD69JC61J
| KEGG = D04185

<!--Chemical data-->
| C=15 | H=20 | N=2 | O=4 
| molecular_weight = 292.33 g/mol
| smiles = CC(=NOC(=O)N)C1=CC(=C(C=C1)OC)OC2CCCC2
}}

'''Filaminast''' (code name '''WAY-PDA 641''')<ref>[https://pubchem.ncbi.nlm.nih.gov/compound/9578243?from=summary#section=Top Filaminist entry at Pubchem]</ref> was a drug candidate developed by Wyeth-Ayerst.<ref>Halpin DM. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(4):543-61. {{PMID|19281073}} {{PMC|2650605}}</ref>{{rp|Table 2}} It is a phosphodiesterase 4 inhibitor ([[PDE4 inhibitor]]) and an analog of [[rolipram]], which served as a prototype molecule for several development efforts.<ref>{{Cite journal|doi=10.1038/bjp.2008.297|pmc=2567889|pmid=18660832|title=Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?|year=2008|last1=Giembycz|first1=M A|journal=British Journal of Pharmacology|volume=155|issue=3|pages=288â€“90}}</ref><ref name=McKenna>McKenna, JM and Muller, GW.  Medicinal Chemistry of PDE4 Inhibitors. Chapter 33 in Cyclic Nucleotide Phosphodiesterases in Health and Disease, Eds Joseph A. Beavo et al. CRC Press, Dec 5, 2006 {{ISBN|9781420020847}}</ref>{{rp|668, 678}} It was discontinued after a Phase II trial showed that its [[therapeutic window]] was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules.<ref name=McKenna/>{{rp|678}}

==See also==
* [[Piclamilast]]
* [[Roflumilast]]

== References ==
{{Reflist}}

{{Phosphodiesterase inhibitors}}
{{Drugs for obstructive airway diseases}}

[[Category:Abandoned drugs]]
[[Category:Carbamates]]
[[Category:PDE4 inhibitors]]
[[Category:Phenol ethers]]